TD Cowen raised the firm’s price target on Guardant Health (GH) to $63 from $60. The firm said 2Q was solid as sales beat 10% across Oncology, Shield and Biopharma, and they also issued a healthy guidance raise.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- 3 Best Stocks to Buy Now, 7/31/2025, According to Top Analysts
- Guardant Health’s Strong Performance and Growth Potential Justify Buy Rating Despite V2 Data Delay Concerns
- Guardant Health Reports Strong Q2 2025 Growth
- Guardant Health’s Strong Performance and Strategic Focus Drive Buy Rating
- Guardant Health reports Q2 EPS (44c), consensus (51c)